UROTHELIAL CARCINOMA RECURRENT
Clinical trials for UROTHELIAL CARCINOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA RECURRENT trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat bladder cancer
Disease control Recruiting nowThis phase II trial is testing a drug called trastuzumab rezetecan, either alone or with an immunotherapy drug called adebrelimab, in people with advanced bladder cancer that has a protein called HER2. The study aims to see if these treatments can shrink tumors or slow the cancer…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New BCG vaccine could be just as good for bladder cancer
Disease control Recruiting nowThis phase 3 trial is testing a new version of the BCG vaccine, called Verity-BCG, against the standard BCG treatment (OncoTICE) in 540 people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if Verity-BCG is a…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE3 • Sponsor: Verity Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC